BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 38716606)

  • 1. [Role and progress of allogeneic hematopoietic stem cell transplantation in the treatment of refractory/relapsed diffuse large B-cell lymphoma].
    Cao LQ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):308-312. PubMed ID: 38716606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
    Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Kato K; Sugio T; Ikeda T; Yoshitsugu K; Miyazaki K; Suzumiya J; Yamamoto G; Kim SW; Ikegame K; Uehara Y; Mori Y; Ishikawa J; Hiramoto N; Eto T; Nakazawa H; Kobayashi H; Serizawa K; Onizuka M; Fukuda T; Atsuta Y; Suzuki R
    Bone Marrow Transplant; 2024 Mar; 59(3):306-314. PubMed ID: 38102209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
    Epperla N; Hamadani M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.
    Xiao Z; Li J; Miao K
    Curr Stem Cell Res Ther; 2017; 12(1):14-18. PubMed ID: 27396370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress of Auto-HSCT for Treatment of DLBCL--Review].
    Wang X; Xia B; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1841-1846. PubMed ID: 30501731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy.
    Hilal T; Mountjoy LJ
    Curr Oncol Rep; 2023 Jun; 25(6):599-607. PubMed ID: 36976461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts.
    Uhm J; Kuruvilla J
    Transfus Apher Sci; 2013 Aug; 49(1):63-71. PubMed ID: 23790650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
    Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
    Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
    Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
    Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
    Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation for lymphoma.
    Dean RM; Bishop MR
    Clin Lymphoma; 2004 Mar; 4(4):238-49. PubMed ID: 15072616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.
    Lee CH; Lin TC; Yao M; Hsiao LT; Ko BS; Liu CJ; Chen TY
    Cancer Med; 2023 Dec; 12(24):21761-21769. PubMed ID: 38018321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
    Jeyakumar N; Smith M
    Front Immunol; 2022; 13():887866. PubMed ID: 35663947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?
    Dreger P; Fenske TS; Montoto S; Pasquini MC; Sureda A; Hamadani M;
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):e77-e85. PubMed ID: 31917272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
    Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
    Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.